Bond.az White LogoBond.az Black Logo

Ceragon Q1 2026 Revenue Beats Estimates

Ceragon Networks Q1 2026 revenue beat estimates at $85M. EPS $0.01. Stock rose 6.77% premarket. Full-year guidance reiterated.

Sarah Johnson
BySarah Johnson- Senior Editor
|
0

Ceragon Networks (CRNT) reported Q1 2026 revenue of $85 million, exceeding the forecast of $80.36 million. EPS met expectations at $0.01.

The positive revenue surprise of 5.77% drove the stock up 6.77% in premarket trading to $2.58. The company maintains its 2026 revenue guidance of $355-$385 million.

Strong demand in India and North America, particularly for the IP-50EXA platform, underpins the outlook. Despite supply chain challenges, Ceragon expects sequential growth.

Bond.az notes the company's improving competitive position and strategic focus on fixed wireless access and private networks.

More News
Today / 14:20
|
888

Home Depot Q1 2026 earnings beat forecasts, stock dips

Home Depot Q1 2026 earnings beat forecasts with EPS of $3.43 and revenue of $41.8B. Stock dips 2.49% amid margin concerns.

0
Today / 14:03
|
352

Hera Group Q1 2026: Steady growth

Hera Group posts steady growth in Q1 2026 with net profit of EUR 155 million and EPS of $0.105.

0
Today / 14:02
|
259

Oxford Lane Capital NAV drops, stock dips

Oxford Lane Capital Corp reports Q4 FY2026 results: NAV per share down, stock falls 4.03%. CLO yields decline. Read more on challenges and outlook.

0
Today / 13:43
|
246

Driven Brands Q4 2025 Revenue Growth Reported

Driven Brands Q4 2025 revenue grows 7.7% to $460.1M, EPS $0.34. Stock up 1.12%.

0
Today / 13:10
|
739

Fractyl Health Q1 2026 EPS Beat, Shares Surge 23%

Fractyl Health Q1 2026 EPS beat expectations by 76%, shares surged 23% after hours. Revita program data expected in Q4 2026.

0
Today / 13:01
|
272

Antalpha Q1 2026: EPS Misses Forecast, Stock Rises

Antalpha Q1 2026: EPS misses forecast at $0.07, stock rises 2.42%. Revenue up 52% to $20.7M. Web3 AI agent Nina launched. Q2 guidance $11M-$13M.

0
Today / 12:44
|
314

GNFC Q4 profit surges, stock climbs 5.17%

GNFC Q4 FY2026 strong results: revenue up 11%, PAT up 35%, stock rises 5.17%. Chemical segment drives growth.

0
Today / 12:42
|
677

Relmada TX Q1 2026: Loss and stock dip

Relmada Therapeutics Q1 2026 results: stock declines, strong cash position and NDV-01 program in focus.

0
Today / 12:00
|
958

Inovio Beats Q1 2026 EPS Forecast, Stock Slips

Inovio Q1 2026 EPS beats forecasts, but stock falls. Detailed financial analysis and outlook on Bond.az.

0
Today / 11:50
|
449

CytoSorbents Q1 2026 Misses Forecasts, Stock Falls

CytoSorbents Q1 2026 results: EPS of -$0.05 misses estimate, revenue of $8.9M falls short, stock drops 7.53%. Company cuts costs and targets breakeven in H2 2026.

0
Today / 10:53
|
859

IOC Q4 2026 earnings beat expectations

IOC Q4 2026 earnings beat expectations with EPS of 6.15, a 20.59% surprise. Stock rose 2.42%. Record refining throughput and 184% profit growth reported.

0
Today / 09:55
|
635

Dr. Martens Q2 2026: revenue dip, stock surges

Dr. Martens Q2 2026 earnings: stock surges 8.41% despite revenue dip. Consumer-first strategy drives profit growth. Undervalued according to Bond.az analysis.

0
...
Ceragon Q1 2026 Revenue Beats Estimates | Bond.az